Silo Pharma Inc (SILO)

[IVANj]

Lots of vol…. Took 3.15 for a bounce

[Invest-in-America]

FUNNY!!!

[Invest-in-America]

Was just joking, Dude!! (I fully GET all of your reply there, & THANKS!!)

[Laster]

Animal data is no real news.
Stock should drift back and close the gap eventually.
Definitely not a runner on THAT news.
JMO.

[KOmani]

I mean the reason the price broke down was shorting.

Whether those shorts have non-public information is what makes it scummy.

[Laster]

Typical trader response. No clue about how biotechs work.
This animal study announced is just a pump.
Only if I could short a stock. This would have been the one when it was over $6.
Sorry BRO!!!!

[Invest-in-America]

SILO: Heck, that all "Humans" are too, Bro!!!

[Laster]

Just an animal study.
OMG.
This run will be very short lived.
JMO.

[tw0122]

6.91 Silo Pharma shares are trading higher after the company announced study results of SPU-21 for arthritis. The company said SPU-21 is effective in controlling arthritis

[tw0122]

Up 50% nice

[Jaydixson1]

Is this a good one

[Pirateshipatbay]

This looks like buys are coming in here 5.25

[subslover]

R/S are hot? I must have eaten the wrong mushrooms like the ancient Greeks!

[Renee]

SILO moved to the Nasdaq from the OTC:

https://otce.finra.org/otce/dailyList?viewType=Deletions

[Renee]

SILO: one for 50 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

[PennyMaster]

$SILO Nice News out!! Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”

About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:

Hayden IR
Brett Maas
646-536-7331
Email: [e-mail]

https://finance.yahoo.com/news/silo-pharma-announces-positive-results-121500306.html

[subslover]

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
Press Release | 07/27/2022
Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system

ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.

Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.

Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”

About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

[R4000]

Wonder how/if the uplist to the Nas is going... either way I think there is a lot of upside here imo.

[jfk]

'Big runner' is down significantly, and not moving/playing dead. What's going to change that?

[StockHighAlert-]

$SILO We have a big runner setting up here.

[Louied91]

$SILO Silo Pharma Advances Psychedelic Patent Portfolio


https://www.globenewswire.com/news-release/2021/08/25/2286293/0/en/Silo-Pharma-Advances-Psychedelic-Patent-Portfolio.html

Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.

“Each of these PCT applications relates to the continued research and development that Silo Pharma has continued to undertake.” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are excited to have taken this important next step to protect our intellectual property.”

These three PCT applications title listed below along with Silo Pharma’s granted IP expands the potential addressable patient population that needs unique patient-focused therapeutics.

CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN

CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS

CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN

The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications.

[StockHighAlert-]

#BreakingNews: $SILO Silo Pharma Advances #Psychedelic Patent Portfolio @TENAssociates https://yhoo.it/2WlSbM6

[StockHighAlert-]

$SILO 8k report released https://t.co/LnGKLX6h3F @TENAssociates

[StockHighAlert-]

$SILO #SiloPharma Secures #Patent that May be Used for #Psychedelics Delivery #Technology @TENAssociates https://www.cannabisfn.com/silo-pharma-secures-patent-that-may-be-used-for-psychedelics-delivery-technology/

[StockHighAlert-]

$Silo Pharma Stock Vs. $Silo Wellness Stock: What’s the Difference? @TENAssociates https://cnafinance.com/silo-pharma-stock-vs-silo-wellness-stock-whats-the-difference/

[StockHighAlert-]

$SILO Keep on radar more news/updates coming soon.. @TENAssociates https://yhoo.it/37zvyGa

[StockHighAlert-]

$Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research https://finance.yahoo.com/news/silo-pharma-announces-jv-partner-121000941.html

[Louied91]

$SILO Silo Pharma Announces that JV partner Zylo Therapeutics Successfully Completes Initial Inspection for Ketamine Intradermal Research

https://www.globenewswire.com/news-release/2021/08/11/2278771/0/en/Silo-Pharma-Announces-that-JV-partner-Zylo-Therapeutics-Successfully-Completes-Initial-Inspection-for-Ketamine-Intradermal-Research.html

Englewood Cliffs NJ, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that Silo’s joint venture partner, ZYLO Therapeutics, completed its first inspection with the SC Board of Pharmacy and will move forward with the Department of Health and Environmental Control.

Eric Weisblum, CEO of Silo Pharma stated “Completion of the first inspection is an important step forward in our goal to develop a transdermal Ketamine therapeutic with the patented Z-Pod® technology. The potential ability to deliver Ketamine or Psilocybin in a time-released and dosage controlled manner would be ground-breaking and we intend to continue exploring this exciting opportunity.”

[StockHighAlert-]

$SILO Silo Pharma presents at Proactive's One2One virtual investor forum @TENAssociates

[StockHighAlert-]

$SILO Load more while you can! Hearing News dropping any day now! @TENAssociates

[swingingRichard]

Nope. Wrong again.

[StockHighAlert-]

$SILO "We are pleased to have been granted this patent by the United States Patent and Trademark Office for our novel homing peptide," said Eric Weisblum, CEO of Silo Pharma. "We will continue to expand our intellectual property portfolio related to markets where our novel therapeutics can be applied.”https://finance.yahoo.com/news/silo-pharma-awarded-notice-allowance-120800480.html

[aCryptoKing]

Could you elaborate on what you mean by "being clever with OTC stocks which usually damages the SH"


If you have specifics I'd like to hear about them... Thank you!

[aCryptoKing]

Would you mind sharing why you like this particular stock?

I'm looking for cohorts to compare but not finding as many as I thought I would. Any reason for following this particular company?

Thanking you in advance

[aCryptoKing]

Any dilution here or explanation for the downward breakout

Serious responses only please

Thank you!

[aCryptoKing]

Can anyone here identify if SILO is into shrooms?

Serious question. Looking for a legit penny stock whose main focus is bringing the psychoactive properties of shrooms to market

Thanks people!

[AlphaStockNews]

$SILO is setting the stage for strong growth in the market this morning after announcing it has entered into a research agreement. https://cnafinance.com/silo-pharma-silo-stock-to-climb-on-research-agreement/

[AlphaStockNews]

$SILO is gearing up for gains after the company announced an extension to an exclusive agreement. Here's what you need to know. https://cnafinance.com/silo-pharma-silo-stock-announces-agreement-extension/

[sickpuppy]

I have two questions about this stock. One what dose (QB) flowing Silo Pharma stand for. Two I read that they trying to up list to the Nasdaq exchange on the board here is already NASD. Is this not the Nasdaq already?

[The GidDy uP Kid]

That is interesting news... GidDy uP SILO...
Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson’s disease has been submitted for ethics board review.

[The GidDy uP Kid]

SILO... fiLLed some .24 range today... News from the other day... GidDy uP SILO...
Silo Pharma Submits Application for NASDAQ up-listingPress Release | 05/25/2021

Englewood Cliffs, NJ, May 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, is pleased to announce that it has submitted its initial application to list on the NASDAQ Capital Market (“NASDAQ”).
https://www.otcmarkets.com/stock/SILO/news/Silo-Pharma-Submits-Application-for-NASDAQ-up-listing?id=304496

[AlphaStockNews]

$SILO is likely to scream for the top in the market this morning after the company announced positive news surrounding a clinical study. https://cnafinance.com/silo-pharma-silo-stock-sets-the-stage-for-tremendous-growth/

[AlphaStockNews]

$SILO is likely going to climb as the opening bell rings after the company announced it entered into a joint venture. https://cnafinance.com/silo-pharma-silo-stock-to-climb-on-joint-venture-news/

[AlphaStockNews]

$SILO is likely to scream for the top in the market today after the company announced plans to uplist to the NASDAQ. https://cnafinance.com/silo-pharma-silo-stock-plans-uplisting-to-the-nasdaq/

[AlphaStockNews]

$SILO is a developmental stage biotech company focused on the development of psychedellic-based therapeutics, presenting a huge opportunity. https://cnafinance.com/silo-pharma-silo-stock-this-stock-is-a-huge-opportunity/

[AlphaStockNews]

$SILO is setting the stage for tremendous gains after announcing an exclusive option that will push it into the RA market. https://cnafinance.com/silo-stock-silo-pharma-jumps-into-rheumatoid-arthritis/

[NovaWahoo]

SILO = future of pharmaceuticals!!

Magic Mushrooms can do so much for so many!

CA on the verge of legalizing them:

https://www.nbcnews.com/news/us-news/new-california-bill-would-decriminalize-psychedelics-expunge-criminal-records-n1258261

Go SILO!!!

Currently .36/.40

#NeverSell

[AlphaStockNews]

$AIKI sends $SILO through the roof! https://finance.yahoo.com/news/aikido-pharma-enters-letter-intent-133000299.html

[billionsmatter]

Breaking News Hits Wire! SILO Announces Reaches Terms with
University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Dear Fellow Trader,

Immediately turn your attention to Silo Pharma Inc. (SILO)

SILO just released news today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.

News Link Here - snapshot below

JANUARY 26, 2021

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.

The exercise of the option agreement allows for Silo to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, which we expect to finalize shortly.

Mr. Eric Weisblum, Chairman and CEO of Silo Pharma, commented, “Silo is pleased to advance our research collaboration with UMB in the fight against Neuroinflammatory diseases. We are focused on the development of this novel therapeutic targeting those who have been afflicted with CNS inflammatory diseases. Management looks forward to sharing the preclinical results of this Novel Homing Peptide upon completion of our initial study in connection with UMB."

If you haven't yet read SILO full profile, do so HERE

Click here to get the full Report!

This could be the beginning of a Massive Short Squeeze and has the Potential to Send Shares Soaring Much Much Higher.

As you know, a “Short Squeeze” is a Stock Market Phenom that can send shares of a stock Dramatically Higher in a short period of time—generally anywhere from a few hours to a few days. Any stock is susceptible to a short squeeze, but those with low volume are especially vulnerable.

...Now take a look at the Short Report on SILO:

Image

Last Thursday, 60.34% of the volume was Short… then on Friday an astounding 65.12% of SILO’s volume was Short... Then yesterday 61.29% of the volume was Short.

These Shorts will have to cover and this could potentially cause a Short Squeeze and send shares of SILO Soaring…

You do not want to miss out on SILO… especially if we see signs of a Short Squeeze about to Send Shares Soaring.

If you haven't taken a look at this stock yet, this is your chance. Make sure you have SILO pulled up on your trading screen.

Sincerely,
Editor In Chief, OTCtipReporter Team
[url]
https://www.otctipreporter.com/[/url][tag]insert-text-here[/tag]

[billionsmatter]

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma, Inc.

Tue, January 26, 2021, 8:18 AM·2 min read

Englewood Cliffs, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders, announced today it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.


https://finance.yahoo.com/news/silo-pharma-reaches-terms-university-131800548.html